EnCompass Technologies has reported the successful utilisation of its new F2 cerebral embolic filter in three transcatheter aortic valve replacement (TAVR) surgeries.

These surgeries were performed last month at the Israeli-Georgian Medical Research Clinic in Tbilisi, Georgia.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It marked the world’s first use of EnCompass’ medical device to protect against brain injury.

EnCompass created an innovative filter device to keep debris away from the brain, helping to lower the risk of brain injury.

The F2 filter provides significant improvements compared to earlier embolic protection devices, including complete coverage of all three major vessels supplying the brain and stability throughout the entire TAVR procedure.

It also offers better micropore filtration to further decrease the size and amount of embolic debris that can reach the brain.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

EnCompass Technologies CEO George Wallace said: “The EnCompass F2filter was designed with pores small enough to trap most harmful debris while preserving blood flow to the brain and the UCLA study results show it is doing precisely what it was designed for.”

Dr Naoki Kaneko led a study with the filter, conducted at the University of California Los Angeles (UCLA) before the pilot clinical study.

In a benchtop simulation, the F2 filter significantly decreased the burden of cerebral microemboli, surpassing the performance of the leading filter in the market.

All three patients received percutaneous administration of the F2 filter before TAVR in the pilot clinical trial.

According to the company, no complications were reported and all the patients recovered without any signs of brain injury.

EnCompass aims to conduct further clinical testing on the F2 filter before making it widely accessible.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
HemoSonics has won the 2025 Marketing Award for its impactful promotion of theQuantra Hemostasis System and leadership in blood management education. See how targeted campaigns, thought leadership content, and hands on clinician training are accelerating Quantra’s market traction and shaping the future of hemostasis testing.

Discover the Impact